Avadel Pharmaceuticals PLC (AVDL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Avadel Pharmaceuticals PLC (AVDL) has a cash flow conversion efficiency ratio of 0.237x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($23.26 Million) by net assets ($98.22 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is Avadel Pharmaceuticals PLC's balance sheet to measure how much of total assets are equity-financed.
Avadel Pharmaceuticals PLC - Cash Flow Conversion Efficiency Trend (1996–2024)
This chart illustrates how Avadel Pharmaceuticals PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check AVDL cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Avadel Pharmaceuticals PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Avadel Pharmaceuticals PLC ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
John Wiley & Sons
NYSE:WLY
|
0.240x |
|
Íslandsbanki hf.
IC:ISB
|
0.079x |
|
Navitas Semiconductor Corp
NASDAQ:NVTS
|
-0.027x |
|
H&R Real Estate Investment Trust
TO:HR-UN
|
0.007x |
|
Maanshan Iron & Steel Co Ltd
SHG:600808
|
-0.004x |
|
Stewart Information Services Corp
NYSE:STC
|
0.054x |
|
momo.com Inc
TW:8454
|
0.128x |
|
Vincom Retail JSC
VN:VRE
|
-0.005x |
Annual Cash Flow Conversion Efficiency for Avadel Pharmaceuticals PLC (1996–2024)
The table below shows the annual cash flow conversion efficiency of Avadel Pharmaceuticals PLC from 1996 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Avadel Pharmaceuticals PLC.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $73.85 Million | $-46.91 Million | -0.635x | +56.63% |
| 2023-12-31 | $87.74 Million | $-128.51 Million | -1.465x | -144.05% |
| 2022-12-31 | $-21.14 Million | $-70.30 Million | 3.325x | +436.50% |
| 2021-12-31 | $78.24 Million | $-77.31 Million | -0.988x | -228.99% |
| 2020-12-31 | $162.27 Million | $-48.73 Million | -0.300x | -122.88% |
| 2019-12-31 | $-29.20 Million | $-38.33 Million | 1.313x | +104.41% |
| 2018-12-31 | $2.78 Million | $-82.72 Million | -29.754x | -15200.73% |
| 2017-12-31 | $84.56 Million | $16.66 Million | 0.197x | -56.14% |
| 2016-12-31 | $42.07 Million | $18.90 Million | 0.449x | -63.83% |
| 2015-12-31 | $67.86 Million | $84.29 Million | 1.242x | +391.22% |
| 2014-12-31 | $24.89 Million | $-10.62 Million | -0.427x | -119.62% |
| 2013-12-31 | $-9.51 Million | $-20.68 Million | 2.174x | +386.55% |
| 2012-12-31 | $30.50 Million | $-23.14 Million | -0.759x | -118.93% |
| 2011-12-31 | $29.79 Million | $-10.32 Million | -0.346x | -130.51% |
| 2010-12-31 | $36.30 Million | $-5.46 Million | -0.150x | -182.29% |
| 2009-12-31 | $44.86 Million | $8.20 Million | 0.183x | +218.11% |
| 2008-12-31 | $48.55 Million | $-7.51 Million | -0.155x | +56.09% |
| 2007-12-31 | $54.63 Million | $-19.24 Million | -0.352x | +13.76% |
| 2006-12-31 | $73.03 Million | $-29.83 Million | -0.408x | -82.54% |
| 2005-12-31 | $86.65 Million | $-19.39 Million | -0.224x | -529.51% |
| 2004-12-31 | $116.76 Million | $-4.15 Million | -0.036x | -126.76% |
| 2003-12-31 | $92.06 Million | $12.23 Million | 0.133x | -81.40% |
| 2002-12-31 | $12.29 Million | $8.77 Million | 0.714x | +292.55% |
| 2001-12-31 | $7.51 Million | $-2.78 Million | -0.371x | +28.24% |
| 2000-12-31 | $10.88 Million | $-5.62 Million | -0.517x | -10.51% |
| 1999-12-31 | $9.07 Million | $-4.24 Million | -0.468x | -1.55% |
| 1998-12-31 | $17.79 Million | $-8.19 Million | -0.460x | +26.03% |
| 1997-12-31 | $14.30 Million | $-8.90 Million | -0.622x | -242.31% |
| 1996-12-31 | $23.10 Million | $-4.20 Million | -0.182x | -- |
About Avadel Pharmaceuticals PLC
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name… Read more